| Literature DB >> 21639722 |
Riitta Luoto1, Jaana Moilanen, Reetta Heinonen, Tomi Mikkola, Jani Raitanen, Eija Tomas, Katriina Ojala, Kirsi Mansikkamäki, Clas-Håkan Nygård.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2011 PMID: 21639722 PMCID: PMC3469216 DOI: 10.3109/07853890.2011.583674
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 4.709
Figure 1Participant flow in a randomized aerobic training trial.
Base-line characteristics and quality of life in the intervention and control groups. QoL was estimated by means of the Short Form-36 quality of life (SF-36) score and the menopause-specific quality of life score (Women's Health Questionnaire (WHQ)).
| Intervention | Control | Missing (intervention, control) | ||
|---|---|---|---|---|
| Age, y | 54.5±3.8 | 54.2±3.7 | 0.73 | − |
| University degree, % | 24.3 | 26.0 | 0.82 | − |
| Employed, % | 83.6 | 77.6 | 0.36 | 1, 1 |
| Smoker or occasional smoker, % | 18.1 | 11.7 | 0.27 | 2, 0 |
| Weight, kg | 70.5 ±11.4 | 71.7±12.5 | 0.56 | − |
| Body mass index, kg/m2 | 26.3±4.0 | 26.9±4.3 | 0.42 | − |
| Follicle-stimulating hormone (FSH), mmol/L | 65.4±21.2 | 60.2±24.1 | 0.16 | − |
| Thyroid-stimulating hormone (TSH), mmol/L | 2.40±1.96 | 2.72±1.82 | 0.28 | − |
| Weekly frequency of hot flushes, % | ||||
| <29.5 | 31.9 | 37.8 | ||
| 30–49.5 | 31.9 | 23.0 | ||
| >50 | 36.2 | 39.2 | 0.48 | 5, 3 |
| Health-related quality of life | ||||
| SF-36 physical component score | ||||
| Physical functioning | 90 (20–100) | 90 (40–100) | 0.39 | − |
| Role–physical | 100 (0–100) | 100 (0–100) | 0.44 | 1, 1 |
| Bodily pain | 67.5 (0–100) | 67.5 (22.5–100) | 0.30 | 1, 0 |
| General health | 65 (10–95) | 65 (25–100) | 0.72 | 1, 0 |
| SF-36 mental component score | ||||
| Vitality | 65 (5–95) | 60 (0–90) | 0.28 | − |
| Social functioning | 87.5 (25–100) | 87.5 (12.5–100) | 0.33 | 1, 0 |
| Role–emotional | 100 (0–100) | 100 (0–100) | 0.60 | 1, 1 |
| Mental health | 76 (4–100) | 76 (24–100) | 0.46 | − |
| Menopause-specific quality of life | ||||
| Depressed mood | 0.14 (0–0.86) | 0.14 (0–0.86) | 0.18 | − |
| Somatic symptoms | 0.43 (0–1) | 0.43 (0–0.86) | 0.84 | 2, 1 |
| Memory/concentration | 0.67 (0–1) | 0.67 (0–1) | 0.44 | 1, 0 |
| Vasomotor symptoms | 1.00 (0–1) | 1.00 (0–1) | 0.54 | 2, 1 |
| Anxiety/fears | 0.13 (0–1) | 0.25 (0–0.75) | 0.59 | − |
| Sexual behaviour | 0.33 (0–1) | 0.33 (0–1) | 0.63 | 15, 26 |
| Sleep problems | 0.33 (0–1) | 0.67 (0–1) | 0.30 | 0, 0 |
| Menstrual symptoms | 0.33 (0–1) | 0.33 (0–1) | 0.73 | 2, 1 |
| Attractiveness | 0.00 (0–1) | 0.00 (0–1) | 0.53 | 3, 1 |
Differences between groups were tested by Student's t test (continuous variables, normal distributions), the Mann–Whitney U test (continuous variables, non-normal distributions), or the chi-square test (categorical or dichotomized variables). Values are shown as means ± SD, medians and ranges, or percentages.
Women's Health Questionnaire and SF-36 health-related quality-of-life scores among the intervention and control groups—6 month intervention scores and change from base-line to end.
| End intervention | Control | Change intervention | Control | |||
|---|---|---|---|---|---|---|
| Health-related quality of life | ||||||
| SF-36 physical component score | ||||||
| Physical functioning | 89.0 (13.5) | 87.1 (14.8) | 0.33 | 2.67 (10.8) | –0.64 (9.38) | 0.049 |
| Role–physical | 81.4 (29.3) | 77.3 (33.5) | 0.48 | 5.14 (27.9) | –3.95 (30.0) | 0.017 |
| Bodily pain | 69.4 (21.1) | 70.2 (24.9) | 0.65 | 0.72 (19.0) | –3.08 (21.4) | 0.32 |
| General health | 66.9 (21.1) | 65.1 (20.0) | 0.55 | 3.01 (12.3) | –0.45 (12.1) | 0.065 |
| SF-36 mental component score | ||||||
| Vitality | 66.9 (18.9) | 58.3 (23.8) | 0.023 | 5.72 (14.2) | –0.13 (16.3) | 0.062 |
| Social functioning | 86.0 (19.6) | 79.9 (25.1) | 0.17 | 3.25 (19.1) | 1.62 (20.9) | 0.82 |
| Role–emotional | 85.6 (27.1) | 78.4 (31.9) | 0.12 | 6.85 (25.4) | 3.07 (34.9) | 0.46 |
| Mental health | 78.1 (15.9) | 72.7 (17.6) | 0.021 | 3.51 (11.9) | 0.25 (13.2) | 0.097 |
| Menopause-specific quality of life score (WHQ) | ||||||
| Depressed mood | 0.12 (0.20) | 0.22 (0.21) | <0.001 | –0.07 (0.16) | –0.02 (0.15) | 0.023 |
| Somatic symptoms | 0.42 (0.30) | 0.41 (0.26) | 0.96 | –0.04 (0.23) | –0.02 (0.17) | 0.64 |
| Memory/concentration | 0.49 (0.35) | 0.50 (0.38) | 0.84 | –0.03 (0.30) | –0.07 (0.34) | 0.53 |
| Vasomotor symptoms | 0.83 (0.32) | 0.85 (0.28) | 0.92 | –0.10 (0.37) | –0.05 (0.25) | 0.30 |
| Anxiety/fears | 0.17 (0.26) | 0.19 (0.22) | 0.25 | –0.04 (0.16) | –0.02 (0.17) | 0.82 |
| Sexual behaviour | 0.38 (0.35) | 0.43 (0.34) | 0.39 | –0.02 (0.27) | –0.02 (0.24) | 0.94 |
| Sleep problems | 0.37 (0.33) | 0.45 (0.30) | 0.072 | –0.08 (0.28) | –0.05 (0.26) | 0.28 |
| Menstrual symptoms | 0.26 (0.29) | 0.31 (0.32) | 0.32 | –0.08 (0.25) | –0.05 (0.29) | 0.47 |
| Attractiveness | 0.17 (0.30) | 0.30 (0.39) | 0.041 | –0.10 (0.31) | –0.01 (0.28) | 0.062 |
P for difference between the groups; Mann—Whitney test.
Number of responses to phone-based diary and observed frequency (%) of hot flushes by intervention month and group. Estimated proportion of hot flushes from multilevel mixed logistic regression.
| Intervention group | Control group | |||||||
|---|---|---|---|---|---|---|---|---|
| Month | Responses | Number of responses with hot flushes | Observed proportion of responses with hot flushes (%) | Estimated proportion of hot flushes from mixed model | Responses | Number of responses with hot flushes | Observed proportion of responses with hot flushes (%) | Estimated proportion of hot flushes from mixed model |
| Night-time hot flushes: | ||||||||
| 1 (base-line) | 1513 | 867 | 57.3 | 56.1 | 1518 | 920 | 60.6 | 59.7 |
| 2 | 1719 | 948 | 55.1 | 54.3 | 1712 | 1018 | 59.5 | 58.6 |
| 3 | 1629 | 843 | 51.7 | 53.2 | 1576 | 863 | 54.8 | 58.1 |
| 4 | 1611 | 795 | 49.3 | 52.6 | 1581 | 872 | 55.2 | 55.6 |
| 5 | 1552 | 780 | 50.3 | 48.5 | 1503 | 866 | 57.6 | 54.3 |
| 6 (end) | 1314 | 624 | 47.5 | 46.0 | 1361 | 716 | 52.6 | 54.0 |
| Mixed model for day-time hot flushes: | ||||||||
| Day-time hot flushes: | ||||||||
| 1 (base-line) | 1314 | 951 | 72.4 | 68.2 | 1339 | 952 | 71.1 | 68.5 |
| 2 | 1626 | 1080 | 66.4 | 67.1 | 1640 | 1151 | 70.2 | 69.1 |
| 3 | 1537 | 970 | 63.1 | 66.5 | 1542 | 978 | 63.4 | 67.8 |
| 4 | 1495 | 964 | 64.5 | 67.2 | 1446 | 936 | 64.7 | 67.3 |
| 5 | 1386 | 931 | 67.2 | 66.2 | 1463 | 1014 | 69.3 | 66.6 |
| 6 (end) | 1208 | 840 | 69.5 | 66.6 | 1292 | 861 | 66.6 | 65.7 |
Mixed model for day-time hot flushes:
P (group at base-line) = 0.18.
P (month) = 0.005.
P (group X month) = 0.61.
Figure 2Observed weekly frequencies (%) and 95% confidence intervals of day-time (left) and night-time (right) hot flushes based on mobile phone questionnaire during 24 weeks of intervention.
Changes in quality of life (WHQ and SF-36 scores) by frequency of aerobic training sessions (from phone-based diary and heart rate belt information). Intervention group women (n = 78). Significance between the frequency groups tested with non-parametric Kruskal–Wallis test.
| Change (base-line to 6 month) in: | Low (1–49 sessions) | Medium (50–72 sessions) | High (> 72 sessions) | |
|---|---|---|---|---|
| SF-36 | Mean (SD) | Mean (SD) | Mean (SD) | |
| Physical functioning | 2.34 (11.3) | 2.13 (13.2) | 3.46 (8.0) | 0.80 |
| Role–physical | 0.00 (22.1) | 6.25 (28.8) | 9.00 (32.2) | 0.58 |
| Bodily pain | 3.04 (12.4) | –4.58 (19.1) | 3.56 (22.9) | 0.21 |
| General health | 0.83 (11.6) | 0.63 (13.1) | 7.40 (11.4) | 0.096 |
| Vitality | 9.44 (13.0) | 5.35 (15.9) | 2.63 (13.4) | 0.27 |
| Social functioning | 1.56 (23.4) | 0.00 (16.5) | 8.00 (16.5) | 0.22 |
| Role–emotional | 6.94 (31.1) | 5.56 (16.1) | 8.00 (27.7) | 0.99 |
| Mental health | 2.71 (12.6) | 3.50 (11.9) | 4.27 (11.7) | 0.95 |
| WHQ | ||||
| Depressed mood | 0.01 (0.17) | –0.12 (0.16) | –0.09 (0.14) | 0.03 |
| Somatic symptoms | –0.04 (0.23) | 0.04 (0.23) | –0.11 (0.20) | 0.12 |
| Memory/concentration | –0.03 (0.34) | –0.06 (0.25) | –0.02 (0.31) | 0.85 |
| Vasomotor symptoms | –0.04 (0.36) | –0.15 (0.35) | –0.13 (0.40) | 0.52 |
| Anxiety/fears | 0.02 (0.07) | –0.05 (0.16) | –0.08 (0.20) | 0.056 |
| Sexual behaviour | –0.03 (0.22) | –0.03 (0.28) | –0.01 (0.32) | 0.98 |
| Sleep problems | –0.03 (0.17) | –0.11 (0.21) | –0.10 (0.41) | 0.46 |
| Menstrual symptoms | 0.05 (0.23) | –0.16 (0.26) | –0.12 (0.20) | 0.01 |
| Attractiveness | –0.13 (0.22) | –0.04 (0.44) | –0.13 (0.22) | 0.38 |
Missing number of responses: low: SF-36 1, WHQ 5; medium: SF-36 0, WHQ 5; high: SF-36 4, WHQ 16.
Aerobic training-related variables (fitness and body composition) at base-line, after 6 months intervention, and change between base-line and 6 months. Differences between groups were tested by t test.
| Base-line intervention | Control | End intervention | Control | Change intervention | Control | ||||
|---|---|---|---|---|---|---|---|---|---|
| VO2 (mL/kg/min) | 31.7 (5.4) | 31.5 (4.8) | 0.845 | 32.6 (5.2) | 31.4 (5.2) | 0.167 | 0.77 (2.22) | –0.16 (1.83) | 0.008 |
| DXA | |||||||||
| fat mass (kg) | 27.2 (8.8) | 28.3 (8.9) | 0.413 | 26.1 (8.6) | 27.8 (8.8) | 0.262 | –0.90 (1.99) | –0.48 (2.10) | 0.219 |
| lean (muscle mass, kg) | 40.1 (4.3) | 40.2 (4.9) | 0.917 | 40.6 (4.1) | 40.3 (4.6) | 0.705 | 0.57 (1.16) | 0.15 (1.34) | 0.046 |
Missing values: Intervention: base-line 2, 0, and 0; end: 10, 5, and 5; change: 11, 5, and 5; Control: base-line–; end: 4, 3, and 3; change: 4, 3, and 3.
DXA = dual X-ray absorptiometry; VO2 = volume of oxygen consumption.